Meropenem
Meropenem is a carbapenem β-lactam antibacterial agent used to treat serious bacterial infections.
Meropenem is a carbapenem β-lactam antibacterial agent used to treat serious bacterial infections. Its antibacterial activity results from binding to bacterial penicillin-binding proteins and inhibiting peptidoglycan cross-linking, thereby impairing cell-wall synthesis and promoting bacterial cell death. As a β-lactam, its activity is generally related to the duration for which drug concentrations remain above the organism’s minimum inhibitory concentration.
Meropenem has clinical importance against severe infections caused by Gram-negative organisms, including Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii, although susceptibility is limited by β-lactamase-mediated resistance. Metallo-β-lactamases (MBLs), including VIM-1 and New Delhi metallo-β-lactamase-5 (NDM-5), can hydrolyze carbapenems and compromise meropenem activity. Recent research has therefore examined meropenem in combination with enzyme-directed ligands, natural products, metal-oxide nanoparticles, and drug-delivery materials. Other work has addressed its use in meningitis and its comparative safety in antibiotic combinations involving vancomycin, piperacillin/tazobactam, or cefepime.
Where the papers sit
9 papers from the last 6 months study meropenem directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 1 observational · 2 human data · 4 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
Carbapenem Resistance Reversal
Meropenem potentiation is moving toward adjunctive strategies that restore activity against carbapenemase-producing bacteria. SKQ1, emodin, clove oil constituents, and zinc-binding ligands are paired with meropenem against NDM-1, KPC-2, VIM-1, MRSA, and Acinetobacter, with synergy measured by fractional inhibitory concentration and MIC assays. Molecular docking and competitive inhibition support target-directed adjuvant design, but evidence remains predominantly in vitro. The open question is whether these combinations can achieve reliable activity and safety in infection models or patients.
5 papers · 55.6%
-
Beta-Lactam Selection and Dosing
Beta-lactam treatment is being framed as a balance between empiric sepsis coverage, kidney safety, and dosing reliability. Meropenem is being compared with piperacillin/tazobactam in critically ill adults, while vancomycin combinations highlight acute kidney injury concerns with piperacillin/tazobactam versus cefepime or other beta-lactams. The randomized comparison is still at feasibility stage, so superiority on clinical outcomes remains unresolved. Large language models add a cautionary signal: renal precision-dosing recommendations are inconsistent and require clinical verification.
3 papers · 33.3%
-
Pediatric Listeria Meningitis
Non-neonatal Listeria monocytogenes meningitis is being recognized in children with immunosuppression and Crohn's disease, rather than treated as an exclusively neonatal infection. Case descriptions emphasize culture and polymerase chain reaction for diagnosis, with neurological presentations and Glasgow Outcome Scale assessment. The literature remains primarily descriptive, using multicenter cases to define risk factors and outcomes rather than establish comparative therapy. Persistent uncertainty concerns early recognition and management in immunocompromised children.
1 papers · 11.1%
Meropenem becomes a test case for the reliability of large-language-model dosing advice
The subject of PMID 42817723 is LLM-generated precision dosing for cefepime and meropenem in patients with acute kidney injury receiving continuous kidney replacement therapy. Whereas the other papers use meropenem as an antimicrobial, comparator, formulation, or delivery drug, this study makes it a benchmark for evaluating whether automated clinical recommendations are accurate and reproducible. Its finding of inaccurate and inconsistent LLM outputs changes the practical role of meropenem in this work from treatment being optimized to a clinical decision whose automation requires independent validation 42817723Oct.
Papers
The 9 papers from the last 6 months that study meropenem directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Carbapenem Resistance Reversal (5)
- Repurposing SKQ1 as a meropenem potentiator against NDM-1-producing Escherichia coli. Virulence · 9 Sept 2026 PMID 42711660
- Discovery of Emodin as a novel competitive KPC-2 inhibitor through virtual screening: Synergistic efficacy with Meropenem against Carbapenem-resistant Klebsiella pneumoniae infection. Bioorganic chemistry · 6 Sept 2026 PMID 42702130
- Restoring Meropenem Activity Against VIM-1-Producing Klebsiella pneumoniae Through Zinc-Binding Ligands. Chembiochem : a European journal of chemical biology · 26 Aug 2026 PMID 42644634
- Self-Assembling Amphiphilic Cationic Peptide-Based Nanoarchitectures for Soft Biomaterials with Potential Antimicrobial Activity against Clinically Isolated Multidrug-Resistant Bacteria. ACS applied bio materials · 10 Aug 2026 PMID 42573017
- Synergistic Effects of Clove Essential Oil, Eugenol, Isoeugenol Combined with Meropenem against MRSA, Acinetobacter Baumannii, Bacillus spp in Vitro. Current microbiology · 18 Jul 2026 PMID 42470444
Beta-Lactam Selection and Dosing (3)
- User Beware: Inaccuracy and Inconsistency of Large Language Models in Providing Precision Dosing Recommendations for Patients With Kidney Impairment-A Case Series. Pharmacotherapy · 1 Oct 2026 PMID 42817723
- Empirical Meropenem Versus Piperacillin/Tazobactam for Critically Ill Adults With Sepsis: Feasibility of a Randomised Trial. Acta anaesthesiologica Scandinavica · 31 Aug 2026 PMID 42674465
- Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to vancomycin and other beta-lactam agents: a large multicenter retrospective cohort study from China. Microbiology spectrum · 6 Jul 2026 PMID 42405788
Pediatric Listeria Meningitis (1)
- Listeria monocytogenes meningitis beyond the neonatal period: a multicenter case series of previously unpublished pediatric cases from Türkiye. European journal of pediatrics · 8 Aug 2026 PMID 42570017
By study type
Clinical trials (1)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Critically Ill Adults With Sepsis: Feasibility of a Randomised Trial. Acta anaesthesiologica Scandinavica · 31 Aug 2026 PMID 42674465
Observational studies and case reports (1)
- Listeria monocytogenes meningitis beyond the neonatal period: a multicenter case series of previously unpublished pediatric cases from Türkiye. European journal of pediatrics · 8 Aug 2026 PMID 42570017
Human data, design not indexed (2)
- User Beware: Inaccuracy and Inconsistency of Large Language Models in Providing Precision Dosing Recommendations for Patients With Kidney Impairment-A Case Series. Pharmacotherapy · 1 Oct 2026 PMID 42817723
- Self-Assembling Amphiphilic Cationic Peptide-Based Nanoarchitectures for Soft Biomaterials with Potential Antimicrobial Activity against Clinically Isolated Multidrug-Resistant Bacteria. ACS applied bio materials · 10 Aug 2026 PMID 42573017
Preclinical: animal, cell and lab studies (4)
- Repurposing SKQ1 as a meropenem potentiator against NDM-1-producing Escherichia coli. Virulence · 9 Sept 2026 PMID 42711660
- Discovery of Emodin as a novel competitive KPC-2 inhibitor through virtual screening: Synergistic efficacy with Meropenem against Carbapenem-resistant Klebsiella pneumoniae infection. Bioorganic chemistry · 6 Sept 2026 PMID 42702130
- Restoring Meropenem Activity Against VIM-1-Producing Klebsiella pneumoniae Through Zinc-Binding Ligands. Chembiochem : a European journal of chemical biology · 26 Aug 2026 PMID 42644634
- Synergistic Effects of Clove Essential Oil, Eugenol, Isoeugenol Combined with Meropenem against MRSA, Acinetobacter Baumannii, Bacillus spp in Vitro. Current microbiology · 18 Jul 2026 PMID 42470444
Unclassified: not yet indexed with MeSH (1)
- Risk of acute kidney injury in patients on concomitant vancomycin and piperacillin-tazobactam compared to vancomycin and other beta-lactam agents: a large multicenter retrospective cohort study from China. Microbiology spectrum · 6 Jul 2026 PMID 42405788
Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-08-28. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.